DeepScan moves to a new office and opens lab in Helsinki
DeepScan has moved to a new office (with its own laboratory) in Vallila, Helsinki. The new lab supports R&D and sample analysis for the Nordic region, strengthening DeepScan’s in-house capabilities and enabling faster development and validation of its diagnostic tests.
DeepScan welcomes Dr. Zachary Wright as advisor
DeepScan welcomed Dr. Zachary Wright as an advisor. Dr. Wright brings extensive clinical experience and industry insight, supporting DeepScan in clinical strategy, product development, and collaboration with veterinary professionals.
DeepScan and Sploot launch CFD test in Colorado
DeepScan, in collaboration with Sploot, launched the CFD test in Colorado. The launch expands access to DeepScan’s cfDNA-based diagnostics in the US and supports clinics in integrating minimally invasive testing into routine care.
DeepScan at ESVONC in Porto
DeepScan attended ESVONC in Porto, presenting a scientific poster and participating as a speaker. The event provided an important platform to share clinical insights and engage with oncology-focused veterinarians.
DeepScan participating at WVC
DeepScan attended the Western Veterinary Conference (WVC)in Las Vegas, connecting with veterinarians, industry partners, and diagnostics leaders from across the globe.
DeepScan launches with select clinics in Finland
DeepScan officially launched its first diagnostic offering with a group of selected veterinary clinics in Finland. The launch marks the first real-world clinical use of DeepScan’s cfDNA technology.
DeepScan at VMX
DeepScan was present at VMX, one of the world’s largest veterinary conferences. The team met with clinics, partners, and industry stakeholders to discuss next-generation diagnostics.
DeepScan at WEF in Davos
DeepScan participated in meetings and discussions in Davos, engaging with healthcare, diagnostics, and technology leaders on the future of precision diagnostics and data-driven medicine.
DeepScan raises €2M pre-seed
DeepScan has raised €2 million in pre-seed funding to accelerate development of its cfDNA-based diagnostics for companion animals. The round supports product development, clinical validation, and early international expansion.